Literature DB >> 15914973

Consequences of inadequate management of hyponatremia.

Horacio J Adrogué1.   

Abstract

Dilutional hyponatremia is a commonly observed disorder in hospitalized patients. It represents an excess of water in relation to prevailing sodium stores and is most often associated with a high plasma level of arginine vasopressin, including that found in patients with the syndrome of inappropriate antidiuretic hormone secretion. Hyponatremia may be classified as either acute or chronic depending on the rate of decline of serum sodium concentration, and can lead to a wide range of deleterious changes involving almost all body systems. Serious complications of dilutional hyponatremia most frequently involve the central nervous system. In fact, acute severe hyponatremia is potentially life-threatening and must be treated promptly and aggressively. Chronic hyponatremia often develops in patients with nonrenal diseases and is associated with increased morbidity and mortality. In patients hospitalized for congestive heart failure, hyponatremia is linked to a poor prognosis and increased length of hospital stay. Prompt recognition and optimal management of hyponatremia in hospitalized patients may reduce in-hospital mortality and symptom severity, allow for less intensive hospital care, decrease the duration of hospitalization and associated costs, and improve the treatment of underlying comorbid conditions and patients' quality of life. The proper treatment of dilutional hyponatremia, especially when chronic, must avoid increasing serum sodium too rapidly, which can lead to permanent or fatal neurologic sequelae. The treatment of hyponatremia may be facilitated by emerging therapies that block the actions of arginine vasopressin at V2 and V1a receptors to promote aquaresis, the electrolyte-sparing elimination of free water, and elevate serum sodium concentrations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15914973     DOI: 10.1159/000086019

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  27 in total

1.  Medical costs of abnormal serum sodium levels.

Authors:  Alisa M Shea; Bradley G Hammill; Lesley H Curtis; Lynda A Szczech; Kevin A Schulman
Journal:  J Am Soc Nephrol       Date:  2008-01-23       Impact factor: 10.121

2.  Awareness and management of hyponatraemia: the Italian Hyponatraemia Survey.

Authors:  C Giuliani; M Cangioli; P Beck-Peccoz; M Faustini-Fustini; E Fiaccadori; A Peri
Journal:  J Endocrinol Invest       Date:  2013-04-02       Impact factor: 4.256

3.  Clinical management of SIADH.

Authors:  Peter Gross
Journal:  Ther Adv Endocrinol Metab       Date:  2012-04       Impact factor: 3.565

Review 4.  Diagnosis and management of hyponatremia in cancer patients.

Authors:  Jorge J Castillo; Marc Vincent; Eric Justice
Journal:  Oncologist       Date:  2012-05-22

5.  Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.

Authors:  Michael J Roy; Keith A Erdman; Anura T Abeyratne; Lisa C Plumb; Kenneth Lasseter; Dennis S Riff; James J Keirns
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447

Review 6.  Hyponatremia and brain injury: historical and contemporary perspectives.

Authors:  Matthew A Kirkman; Angelique F Albert; Ahmed Ibrahim; Doris Doberenz
Journal:  Neurocrit Care       Date:  2013-06       Impact factor: 3.210

7.  Costs of eprosartan versus diuretics for treatment of hypertension in a geriatric population: an observational, open-label, multicentre study.

Authors:  Joaquin A Alvarez Gregori; Juan F Macías Nuñez; Alfonso Domínguez-Gil
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

8.  Use of conivaptan to allow aggressive hydration to prevent tumor lysis syndrome in a pediatric patient with large-cell lymphoma and SIADH.

Authors:  Pornpimol Rianthavorn; Joan P Cain; Martin A Turman
Journal:  Pediatr Nephrol       Date:  2008-04-24       Impact factor: 3.714

Review 9.  Practical issues for the management of hyponatremia in oncology.

Authors:  Rossana Berardi; Andrea Antonuzzo; Livio Blasi; Roberta Buosi; Vito Lorusso; Maria Rita Migliorino; Vincenzo Montesarchio; Nicoletta Zilembo; Roberto Sabbatini; Alessandro Peri
Journal:  Endocrine       Date:  2018-02-07       Impact factor: 3.633

10.  SIADH and hyponatraemia: why does it matter?

Authors:  Ewout J Hoorn; Nils van der Lubbe; Robert Zietse
Journal:  NDT Plus       Date:  2009-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.